Skip to main content
Erschienen in: Die Gastroenterologie 2/2019

11.03.2019 | Pankreaskarzinom | CME

Duktales Adenokarzinom des Pankreas

verfasst von: Prof. Dr. E. Gallmeier, T. M. Gress

Erschienen in: Die Gastroenterologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das duktale Adenokarzinom ist die häufigste maligne Raumforderung des Pankreas. Trotz großer Forschungsanstrengungen und gradueller Verbesserungen der Diagnostik und Therapie weist es immer noch eine sehr ungünstige Prognose auf. Dieser CME-Fortbildungsbeitrag liefert unter Berücksichtigung der aktuellen deutschen, europäischen und US-amerikanischen Leitlinien einen allgemeinen Überblick zu dieser Erkrankung. Zudem werden ausgewählte aktuelle Aspekte der Epidemiologie, Pathogenese und Genetik sowie Grundprinzipien der Diagnostik und Therapie einschließlich potenzieller zukünftiger Therapieoptionen erörtert.
Fußnoten
1
Nach Finalisierung dieses Manuskripts wurden die Ergebnisse der PRODIGE-24 Studie zur adjuvanten Therapie des PDAC mit FOLFIRINOX publiziert [49]: Es zeigte sich unter Verwendung eines modifizierten (dosisreduzierten) mFOLFIRINOX-Schemas eine im Vergleich zu allen bislang zur Adjuvanz des PDAC publizierten Daten dramatisch verbesserte Gesamtüberlebensrate von 54,4 Monaten im Vergleich zu Gemcitabin, wobei allerdings auch die Gesamtüberlebensrate im Gemcitabin-Arm mit 35,0 Monaten bemerkenswert hoch erscheint. Die deutlich erhöhte Effektivität der mFOLFIRINOX-Therapie ging erwarteter Weise mit einer signifikant erhöhten Nebenwirkungsrate (75,9% versus 52,9%) einher. Auf Grundlage dieser Daten ist anzunehmen, dass sich mFOLFIRINOX zumindest für Patienten in sehr gutem Performance-Status als neuer Standard in der adjuvanten Therapie des PDAC etablieren wird.
 
Literatur
1.
Zurück zum Zitat Fitzgerald TL, Hickner ZJ, Schmitz M et al (2008) Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 37:134–138PubMed Fitzgerald TL, Hickner ZJ, Schmitz M et al (2008) Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 37:134–138PubMed
2.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4. Aufl. World Health Organization (WHO), International Agency for Research on Cancer (IARC), Lyon Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4. Aufl. World Health Organization (WHO), International Agency for Research on Cancer (IARC), Lyon
4.
Zurück zum Zitat Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921PubMed Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921PubMed
5.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30PubMed Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30PubMed
6.
Zurück zum Zitat Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024PubMed Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024PubMed
7.
Zurück zum Zitat Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703 Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
8.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefPubMed Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefPubMed
9.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481PubMed Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481PubMed
10.
Zurück zum Zitat Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52CrossRefPubMed Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52CrossRefPubMed
11.
Zurück zum Zitat Cancer Genome Atlas Research Network Electronic address aadhe, cancer genome atlas research N (2017) integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32:185–203.e13 Cancer Genome Atlas Research Network Electronic address aadhe, cancer genome atlas research N (2017) integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32:185–203.e13
12.
Zurück zum Zitat Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedPubMedCentral Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedPubMedCentral
13.
Zurück zum Zitat Waddell N, Pajic M, Patch AM et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501PubMedPubMedCentral Waddell N, Pajic M, Patch AM et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501PubMedPubMedCentral
14.
Zurück zum Zitat Witkiewicz AK, McMillan EA, Balaji U et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744PubMed Witkiewicz AK, McMillan EA, Balaji U et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744PubMed
15.
Zurück zum Zitat Roberts NJ, Norris AL, Petersen GM et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6:166–175PubMed Roberts NJ, Norris AL, Petersen GM et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6:166–175PubMed
17.
Zurück zum Zitat Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617PubMed Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617PubMed
18.
Zurück zum Zitat Bartsch DK, Slater EP, Carrato A et al (2016) Refinement of screening for familial pancreatic cancer. Gut 65:1314–1321PubMed Bartsch DK, Slater EP, Carrato A et al (2016) Refinement of screening for familial pancreatic cancer. Gut 65:1314–1321PubMed
19.
Zurück zum Zitat Korc M, Jeon CY, Edderkaoui M et al (2017) Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 31:529–536PubMedPubMedCentral Korc M, Jeon CY, Edderkaoui M et al (2017) Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 31:529–536PubMedPubMedCentral
20.
Zurück zum Zitat Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68PubMed Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68PubMed
21.
Zurück zum Zitat Maisonneuve P, Lowenfels AB (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 44:186–198PubMed Maisonneuve P, Lowenfels AB (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 44:186–198PubMed
22.
Zurück zum Zitat Hruban RH, Goggins M, Parsons J et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969–2972PubMed Hruban RH, Goggins M, Parsons J et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969–2972PubMed
23.
Zurück zum Zitat Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMed Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMed
24.
Zurück zum Zitat Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260PubMed Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260PubMed
25.
Zurück zum Zitat Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39:1730–1741PubMedPubMedCentral Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39:1730–1741PubMedPubMedCentral
26.
Zurück zum Zitat Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Chichester, Hoboken Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Chichester, Hoboken
27.
Zurück zum Zitat Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197PubMed Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197PubMed
28.
Zurück zum Zitat Mujica VR, Barkin JS, Go VL (2000) Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 21:329–332PubMed Mujica VR, Barkin JS, Go VL (2000) Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 21:329–332PubMed
29.
Zurück zum Zitat Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511PubMed Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511PubMed
30.
Zurück zum Zitat Seufferlein T, Porzner M, Becker T et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51:1395–1440PubMed Seufferlein T, Porzner M, Becker T et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51:1395–1440PubMed
31.
Zurück zum Zitat Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441–447PubMed Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441–447PubMed
32.
Zurück zum Zitat Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentral Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentral
33.
Zurück zum Zitat Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186PubMed Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186PubMed
34.
Zurück zum Zitat Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 146:291–304.e1PubMed Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 146:291–304.e1PubMed
35.
Zurück zum Zitat Bipat S, Phoa SS, van Delden OM et al (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29:438–445PubMed Bipat S, Phoa SS, van Delden OM et al (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29:438–445PubMed
36.
Zurück zum Zitat Nawaz H, Fan CY, Kloke J et al (2013) Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 14:484–497PubMed Nawaz H, Fan CY, Kloke J et al (2013) Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 14:484–497PubMed
37.
Zurück zum Zitat Okasha HH, Naga MI, Esmat S et al (2013) Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound 2:190–193PubMedPubMedCentral Okasha HH, Naga MI, Esmat S et al (2013) Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound 2:190–193PubMedPubMedCentral
38.
Zurück zum Zitat Micames C, Jowell PS, White R et al (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58:690–695PubMed Micames C, Jowell PS, White R et al (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58:690–695PubMed
39.
Zurück zum Zitat Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1028–1061PubMed Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1028–1061PubMed
40.
Zurück zum Zitat Barreto SG, Windsor JA (2016) Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 17:e118–e124PubMed Barreto SG, Windsor JA (2016) Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 17:e118–e124PubMed
41.
Zurück zum Zitat Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of Multimodality therapy. Ann Surg Oncol 22:3409–3413PubMed Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of Multimodality therapy. Ann Surg Oncol 22:3409–3413PubMed
42.
Zurück zum Zitat Lutz MP, Zalcberg JR, Ducreux M et al (2017) 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 79:41–49PubMed Lutz MP, Zalcberg JR, Ducreux M et al (2017) 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 79:41–49PubMed
43.
Zurück zum Zitat Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137PubMedPubMedCentral Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137PubMedPubMedCentral
44.
Zurück zum Zitat Reames BN, Ghaferi AA, Birkmeyer JD et al (2014) Hospital volume and operative mortality in the modern era. Ann Surg 260:244–251PubMed Reames BN, Ghaferi AA, Birkmeyer JD et al (2014) Hospital volume and operative mortality in the modern era. Ann Surg 260:244–251PubMed
45.
Zurück zum Zitat Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585PubMed Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585PubMed
46.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081PubMed Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081PubMed
47.
Zurück zum Zitat Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMed Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMed
48.
Zurück zum Zitat Nagrial AM, Chang DK, Nguyen NQ et al (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 110:313–319PubMed Nagrial AM, Chang DK, Nguyen NQ et al (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 110:313–319PubMed
49.
Zurück zum Zitat Conroy T et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406PubMed Conroy T et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406PubMed
50.
Zurück zum Zitat Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512PubMed Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512PubMed
51.
Zurück zum Zitat Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600PubMed Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600PubMed
52.
Zurück zum Zitat Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319PubMed Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319PubMed
53.
Zurück zum Zitat Kim KS, Kwon J, Kim K et al (2017) Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat 49:824–833PubMed Kim KS, Kwon J, Kim K et al (2017) Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat 49:824–833PubMed
54.
Zurück zum Zitat van der Gaag NA, Rauws EA, van Eijck CH et al (2010) Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362:129–137PubMed van der Gaag NA, Rauws EA, van Eijck CH et al (2010) Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362:129–137PubMed
55.
Zurück zum Zitat Tol JA, van Hooft JE, Timmer R et al (2016) Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 65:1981–1987PubMed Tol JA, van Hooft JE, Timmer R et al (2016) Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 65:1981–1987PubMed
56.
Zurück zum Zitat Ettrich TJ, Schulte LA, Eitel N et al (2017) Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent—a multicenter survey in Germany and review of the literature. Z Gastroenterol 55:657–666PubMed Ettrich TJ, Schulte LA, Eitel N et al (2017) Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent—a multicenter survey in Germany and review of the literature. Z Gastroenterol 55:657–666PubMed
57.
Zurück zum Zitat Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos Med 7:e1000267PubMedPubMedCentral Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos Med 7:e1000267PubMedPubMedCentral
58.
Zurück zum Zitat Balaban EP, Mangu PB, Khorana AA et al (2016) Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:2654–2668PubMed Balaban EP, Mangu PB, Khorana AA et al (2016) Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:2654–2668PubMed
59.
Zurück zum Zitat Rombouts SJ, Walma MS, Vogel JA et al (2016) Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 23:4352–4360PubMedPubMedCentral Rombouts SJ, Walma MS, Vogel JA et al (2016) Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 23:4352–4360PubMedPubMedCentral
60.
Zurück zum Zitat Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116PubMed Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116PubMed
61.
Zurück zum Zitat Hurt CN, Mukherjee S, Bridgewater J et al (2015) Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 93:810–818PubMedPubMedCentral Hurt CN, Mukherjee S, Bridgewater J et al (2015) Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 93:810–818PubMedPubMedCentral
62.
Zurück zum Zitat Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326PubMedPubMedCentral Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326PubMedPubMedCentral
63.
Zurück zum Zitat Hammel P, Huguet F, van Laethem JL et al (2016) Effect of cemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853PubMed Hammel P, Huguet F, van Laethem JL et al (2016) Effect of cemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853PubMed
64.
Zurück zum Zitat Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
65.
Zurück zum Zitat Li D, Capanu M, Yu KH et al (2015) Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clin Colorectal Cancer 14:269–276e1PubMedPubMedCentral Li D, Capanu M, Yu KH et al (2015) Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clin Colorectal Cancer 14:269–276e1PubMedPubMedCentral
66.
Zurück zum Zitat Hackert T, Niesen W, Hinz U et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43:358–363PubMed Hackert T, Niesen W, Hinz U et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43:358–363PubMed
67.
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMed Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMed
68.
Zurück zum Zitat Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557PubMed Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557PubMed
69.
Zurück zum Zitat Haas M, Siveke JT, Schenk M et al (2018) Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: a prospective phase II study of the ‚Arbeitsgemeinschaft Internistische Onkologie‘. Eur J Cancer 94:95–103PubMed Haas M, Siveke JT, Schenk M et al (2018) Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: a prospective phase II study of the ‚Arbeitsgemeinschaft Internistische Onkologie‘. Eur J Cancer 94:95–103PubMed
70.
Zurück zum Zitat Sinn M, Bahra M, Liersch T et al (2017) CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35:3330–3337PubMed Sinn M, Bahra M, Liersch T et al (2017) CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35:3330–3337PubMed
71.
Zurück zum Zitat Vogel A, Kullmann F, Kunzmann V et al (2015) Patients with advanced pancreatic cancer and Hyperbilirubinaemia: review and German expert opinion on treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat 38:596–603PubMed Vogel A, Kullmann F, Kunzmann V et al (2015) Patients with advanced pancreatic cancer and Hyperbilirubinaemia: review and German expert opinion on treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat 38:596–603PubMed
72.
Zurück zum Zitat Rahma OE, Duffy A, Liewehr DJ et al (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24:1972–1979PubMedPubMedCentral Rahma OE, Duffy A, Liewehr DJ et al (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24:1972–1979PubMedPubMedCentral
73.
Zurück zum Zitat Portal A, Pernot S, Tougeron D et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 113:989–995PubMedPubMedCentral Portal A, Pernot S, Tougeron D et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 113:989–995PubMedPubMedCentral
74.
Zurück zum Zitat Oettle H, Riess H, Stieler JM et al (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32:2423–2429PubMed Oettle H, Riess H, Stieler JM et al (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32:2423–2429PubMed
75.
Zurück zum Zitat Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‑fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681PubMed Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‑fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681PubMed
76.
Zurück zum Zitat Gill S, Ko YJ, Cripps C et al (2016) PANCREOX: a randomized phase III study of fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received Gemcitabine-based chemotherapy. J Clin Oncol 34:3914–3920PubMed Gill S, Ko YJ, Cripps C et al (2016) PANCREOX: a randomized phase III study of fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received Gemcitabine-based chemotherapy. J Clin Oncol 34:3914–3920PubMed
77.
Zurück zum Zitat Hartung TJ, Brahler E, Faller H et al (2017) The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46–53PubMed Hartung TJ, Brahler E, Faller H et al (2017) The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46–53PubMed
78.
Zurück zum Zitat O’Donnell E (2013) The distress thermometer: a rapid and effective tool for the oncology social worker. Int J Health Care Qual Assur 26:353–359PubMed O’Donnell E (2013) The distress thermometer: a rapid and effective tool for the oncology social worker. Int J Health Care Qual Assur 26:353–359PubMed
79.
Zurück zum Zitat Gotze H, Brahler E, Gansera L et al (2018) Anxiety, depression and quality of life in family caregivers of palliative cancer patients during home care and after the patient’s death. Eur J Cancer Care (engl) 27:e12606 Gotze H, Brahler E, Gansera L et al (2018) Anxiety, depression and quality of life in family caregivers of palliative cancer patients during home care and after the patient’s death. Eur J Cancer Care (engl) 27:e12606
80.
Zurück zum Zitat Ter Veer E, van Rijssen LB, Besselink MG et al (2018) Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 19:e151–e160PubMedPubMedCentral Ter Veer E, van Rijssen LB, Besselink MG et al (2018) Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 19:e151–e160PubMedPubMedCentral
81.
Zurück zum Zitat Wolff RA (2018) Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am 98:95–111PubMed Wolff RA (2018) Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am 98:95–111PubMed
82.
Zurück zum Zitat Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522PubMed Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522PubMed
84.
Zurück zum Zitat Jameson GS, Borazanci EH, Babiker HM et al (2017) A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. J Clin Oncol 35:341–341 Jameson GS, Borazanci EH, Babiker HM et al (2017) A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. J Clin Oncol 35:341–341
85.
Zurück zum Zitat Jameson GS, Borazanci EH, Poplin E et al (2015) Abstract LB-003: High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Cancer Res 75:LB-3–LB-3 Jameson GS, Borazanci EH, Poplin E et al (2015) Abstract LB-003: High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Cancer Res 75:LB-3–LB-3
86.
Zurück zum Zitat Teo MY, O’Reilly EM (2016) Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 7:738–749PubMedPubMedCentral Teo MY, O’Reilly EM (2016) Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 7:738–749PubMedPubMedCentral
87.
Zurück zum Zitat Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site—when a biomarker defines the indication. N Engl J Med 377:1409–1412PubMed Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site—when a biomarker defines the indication. N Engl J Med 377:1409–1412PubMed
88.
Zurück zum Zitat Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24:1326–1336PubMedPubMedCentral Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24:1326–1336PubMedPubMedCentral
90.
Zurück zum Zitat Hingorani SR, Zheng L, Bullock AJ et al (2018) HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 36:359–366PubMed Hingorani SR, Zheng L, Bullock AJ et al (2018) HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 36:359–366PubMed
91.
Zurück zum Zitat Ramanathan RK, McDonough S, Philip PA et al (2018) A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). J Clin Oncol 36(suppl 4S):abstr 208 Ramanathan RK, McDonough S, Philip PA et al (2018) A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). J Clin Oncol 36(suppl 4S):abstr 208
92.
Zurück zum Zitat Lowery MA, Jordan EJ, Basturk O et al (2017) Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 23:6094–6100PubMed Lowery MA, Jordan EJ, Basturk O et al (2017) Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 23:6094–6100PubMed
Metadaten
Titel
Duktales Adenokarzinom des Pankreas
verfasst von
Prof. Dr. E. Gallmeier
T. M. Gress
Publikationsdatum
11.03.2019
Verlag
Springer Medizin
Erschienen in
Die Gastroenterologie / Ausgabe 2/2019
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-019-0340-7

Weitere Artikel der Ausgabe 2/2019

Die Gastroenterologie 2/2019 Zur Ausgabe

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.